Literature DB >> 35035717

Correlation analysis of survivin, ING4, CXCL8 and VEGF expression in prostate cancer tissue.

Lingwei Kong1, Rushan Qi2, Guangchun Zhou1, Sentai Ding3,4.   

Abstract

OBJECTIVE: This study aimed to investigate the expression of Survivin, inhibitor of growth 4 (ING4), CXC chemokine ligand 8 (CXCL8), vascular endothelial growth factor (VEGF), and the correlation between Survivin, ING4, CXCL8 and VEGF in prostate cancer (PCa) tissues.
METHODS: From January 2019 to December 2019, 51 patients from Chengwu People's Hospital and The First People's Hospital of Taian, with PCa were selected as the PCa group and 47 patients with benign prostatic hyperplasia (BPH) were included as the BPH group. The expression of Survivin, ING4, CXCL8 and VEGF in both groups and among patients with different clinical stages in the PCa group were compared, and the correlation between Survivin, ING4, CXCL8 and VEGF expression in PCa tissues was analyzed.
RESULTS: Survivin, ING4, CXCL8, and VEGF expression differed significantly between the two groups (P<0.05). The Survivin positive expression rate, CXCL8 positive expression rate, and VEGF positive expression rate in the PCa group were significantly higher than those in the BPH group (P<0.05), and ING4 positive expression rate in the PCa group was significantly lower than that in the BPH group (P<0.05). Survivin positive expression rate, CXCL8 positive expression rate, and VEGF positive expression rate were significantly higher in PCa patients with stage III+IV than those of stage I+II (P<0.05), and ING4 positive expression rate in PCa patients in stage III+IV was significantly lower than that in stage I+II (P<0.05). Kendall's tau-b analysis, VEGF was positively correlated with Survivin and CXCL8 (P<0.05) and negatively correlated with ING4 (P<0.05) in PCa tissues.
CONCLUSION: Survivin, CXCL8, and VEGF were highly expressed and ING4 was lowly expressed in PCa tissues, which was correlated with clinical stage; additionally, Survivin, ING4, CXCL8, and VEGF played a synergistic role with each other in the development and progression of PCa. AJTR
Copyright © 2021.

Entities:  

Keywords:  CXC chemokine ligand 8; Prostate cancer; growth inhibitory factor; survivin; vascular endothelial growth factor

Year:  2021        PMID: 35035717      PMCID: PMC8748150     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  27 in total

1.  Survivin rs9904341 polymorphism significantly increased the risk of cancer: evidence from an updated meta-analysis of case-control studies.

Authors:  Abdolkarim Moazeni-Roodi; Saeid Ghavami; Mohammad Hashemi
Journal:  Int J Clin Oncol       Date:  2019-02-12       Impact factor: 3.402

2.  Hepatoma Cell-Targeted Cationized Silk Fibroin as a Carrier for the Inhibitor of Growth 4-Interleukin-24 Double Gene Plasmid.

Authors:  Hong Luo; Yongchun Chen; Longxing Niu; Ahui Liang; Jicheng Yang; Mingzhong Li
Journal:  J Biomed Nanotechnol       Date:  2019-07-01       Impact factor: 4.099

Review 3.  Aptamer-based biosensors and nanosensors for the detection of vascular endothelial growth factor (VEGF): A review.

Authors:  Sadegh Dehghani; Rahim Nosrati; Meysam Yousefi; Alireza Nezami; Fatemeh Soltani; Seyed Mohammad Taghdisi; Khalil Abnous; Mona Alibolandi; Mohammad Ramezani
Journal:  Biosens Bioelectron       Date:  2018-03-19       Impact factor: 10.618

4.  ShRNA-mediated knock-down of CXCL8 inhibits tumor growth in colorectal liver metastasis.

Authors:  Abhishek Kumar; Madhuri Cherukumilli; Seyed Hamidreza Mahmoudpour; Karsten Brand; Obul Reddy Bandapalli
Journal:  Biochem Biophys Res Commun       Date:  2018-04-23       Impact factor: 3.575

5.  Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer.

Authors:  K J Helzlsouer; H Y Huang; A J Alberg; S Hoffman; A Burke; E P Norkus; J S Morris; G W Comstock
Journal:  J Natl Cancer Inst       Date:  2000-12-20       Impact factor: 13.506

6.  Computational Outlook of Marine Compounds as Anti-Cancer Representatives Targeting BCL-2 and Survivin.

Authors:  Eram Shakeel; Rajnish Kumar; Neha Sharma; Salman Akhtar; Mohd Kalim Ahmad Khan; Mohtashim Lohani; Mohd Haris Siddiqui
Journal:  Curr Comput Aided Drug Des       Date:  2019       Impact factor: 1.606

7.  Transplantation of Recombinant Vascular Endothelial Growth Factor (VEGF)189-Neural Stem Cells Downregulates Transient Receptor Potential Vanilloid 1 (TRPV1) and Improves Motor Outcome in Spinal Cord Injury.

Authors:  Yun Zeng; Heng Han; Bing Tang; Jie Chen; Dan Mao; Min Xiong
Journal:  Med Sci Monit       Date:  2018-02-21

Review 8.  Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review.

Authors:  Yinzhi Lin; Tamami Ukaji; Naoki Koide; Kazuo Umezawa
Journal:  Int J Mol Sci       Date:  2018-03-03       Impact factor: 5.923

Review 9.  Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP).

Authors:  Zijing Li; Yichi Zhang; Yunru Liao; Rui Zeng; Peng Zeng; Yuqing Lan
Journal:  BMC Ophthalmol       Date:  2018-01-30       Impact factor: 2.209

10.  Inhibitor of Growth 4 (ING4) is a positive regulator of rRNA synthesis.

Authors:  Duc-Anh Trinh; Ryutaro Shirakawa; Tomohiro Kimura; Natsumi Sakata; Kota Goto; Hisanori Horiuchi
Journal:  Sci Rep       Date:  2019-11-21       Impact factor: 4.379

View more
  1 in total

Review 1.  Molecular mechanisms of inhibitor of growth (ING) family members in health and malignancy.

Authors:  Mohammad Taheri; Bashdar Mahmud Hussen; Sajad Najafi; Atefe Abak; Soudeh Ghafouri-Fard; Majid Samsami; Aria Baniahmad
Journal:  Cancer Cell Int       Date:  2022-09-02       Impact factor: 6.429

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.